Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Chronic Spontaneous Urticaria · Asthma

Novartis India

Novartis Pharmaceuticals

Novartis India clinical programs — 121 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mumbai, IN HQ
1996 Founded
2,240 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Founded
1996
Employees
2,240
Programs
341
Drugs
317
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Novartis India projects

121 ClinicalTrials.gov programs sponsored by Novartis India.

Novartis India has 121 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

121 programs

Clinical programs

Page 1 of 3

  1. AUY922

    Novartis Pharmaceuticals

    Advanced HER2-positive Breast Cancer

    phase 2 small molecule completed

    1 trial

  2. Asciminib, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Philadelphia positive Chronic Myeloid leukemia in Chronic Phase with newly diagnosed and resistant/intolerant to previous TKIs, with or without the T315I mutation

    phase 2 small molecule active

    1 trial

  3. BGG492

    Novartis Pharmaceuticals

    Adrenocortical Adenoma

    phase 2 small molecule completed

    1 trial

  4. BGJ398

    Novartis Pharmaceuticals

    Recurrent Glioblastoma or Other Glioma Subtypes

    phase 2 small molecule completed

    1 trial

  5. BION-1301 Single Dose

    Novartis Pharmaceuticals

    IgA Nephropathy

    phase 2 small molecule active

    1 trial

  6. Bion 1301/FUB523

    Novartis Pharmaceuticals

    IgA nephropathy

    phase 2 small molecule active

    1 trial

  7. CAAA601A42101

    Novartis Pharmaceuticals

    Extensive stage small cell lung cancer (ES-SCLC)

    phase 2 small molecule active

    1 trial

  8. CAAA603D12101

    Novartis Pharmaceuticals

    Breast Cancer

    phase 2 small molecule active

    1 trial

  9. CAAA614A12101

    Novartis Pharmaceuticals

    Recurrent or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Metastatic Breast Carcinoma (BC)

    phase 2 small molecule active

    1 trial

  10. CAAA617A12202

    Novartis Pharmaceuticals

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  11. CAAA617B12203

    Novartis Pharmaceuticals

    PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)

    phase 2 small molecule active

    1 trial

  12. CAAA617H12101

    Novartis Pharmaceuticals

    Metastatic neuroendocrine prostate cancer

    phase 2 other active

    1 trial

  13. CAAA802A12101

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial

  14. CABL001E2201

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  15. CABL001I12201

    Novartis Pharmaceuticals

    Pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP), previously treated with one or more tyrosine kinase inhibitors

    phase 2 small molecule active

    1 trial

  16. CABL001L12101

    Novartis Pharmaceuticals

    relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

    phase 2 small molecule active

    1 trial

  17. CADPT09A12201

    Novartis Pharmaceuticals

    Idiopathic pulmonary fibrosis

    phase 2 small molecule active

    1 trial

  18. CADPT15A12201

    Novartis Pharmaceuticals

    Atherosclerotic cardiovascular disease

    phase 2 small molecule active

    1 trial

  19. CADPT17A12201

    Novartis Pharmaceuticals

    Moderate to severe atopic dermatitis

    phase 2 small molecule active

    1 trial

  20. CAMN107AIT15

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  21. CAMO959A12103

    Novartis Pharmaceuticals

    PSMA-positive mCRPC with prior exposure to at least one prior ARPI

    phase 2 small molecule active

    1 trial

  22. CBYL719F12201

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  23. CBYL719F12202

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  24. CBYL719F12401

    Novartis Pharmaceuticals

    PIK3CA-Related Overgrowth Spectrum (PROS)

    phase 2 small molecule active

    1 trial

  25. CBYL719X2402

    Novartis Pharmaceuticals

    Adult patients with PIK3CA mutant, HR-positive, HER2-negative advanced breast cancer

    phase 2 small molecule active

    1 trial

  26. CCFZ533H12201BC

    Novartis Pharmaceuticals

    Moderate to severe hidradenitis suppurativa

    phase 2 small molecule active

    1 trial

  27. CDFV890B12201

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  28. CDZR123A02101

    Novartis Pharmaceuticals

    advanced, solid, relapsed tumors / advanced tumors: human lymphomas / solid human tumor indications (urothelial carcinoma, or other advanced/metastatic solid tumors, ovarian clear cell cancer, endometrial carcinoma, lymphoma including peripheral T-cell Lymphoma and GCBDLBCL, malignant pleural or peritoneal mesothelioma, metastatic castration - resistant prostate cancer (mCRPC))

    phase 2 small molecule active

    1 trial

  29. CDZR123A12107

    Novartis Pharmaceuticals

    Metastatic castrate resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  30. CDZR123C12101

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  31. CECI830A12101

    Novartis Pharmaceuticals

    Advanced solid tumors, Advanced HR+/HER2- breast cancer

    phase 2 small molecule active

    1 trial

  32. CFWY003A12201

    Novartis Pharmaceuticals

    Geographic atrophy secondary to age-related macular degeneration

    phase 2 small molecule active

    1 trial

  33. CGIA632A12201

    Novartis Pharmaceuticals

    Atopic dermatitis

    phase 2 small molecule active

    1 trial

  34. CGVV858A12101

    Novartis Pharmaceuticals

    Advanced HR+/HER- breast cancer

    phase 2 small molecule active

    1 trial

  35. CGXV813B12201

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  36. CINC280A2X02B

    Novartis Pharmaceuticals

    cMET-dependent malignancies

    phase 2 small molecule active

    1 trial

  37. CJDQ443A12101

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  38. CJDQ443E12101

    Novartis Pharmaceuticals

    Adult patients with advanced (metastatic or unresectable) KRAS G12C mutant solid tumors

    phase 2 small molecule active

    1 trial

  39. CJSB462B12201

    Novartis Pharmaceuticals

    Metastatic castration resistant prostate cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  40. CJSB462C12201

    Novartis Pharmaceuticals

    Metastatic hormone-sensitive prostate cancer

    phase 2 small molecule active

    1 trial

  41. CLEE011Q12101

    Novartis Pharmaceuticals

    Relapsed or refractory neuroblastoma and other solid tumors (including medulloblastoma, high grade glioma, malignant rhabdoid tumors, and rhabdomyosarcoma)

    phase 2 small molecule active

    1 trial

  42. CLEE011X2107

    Novartis Pharmaceuticals

    Advanced HR+ breast cancer

    phase 2 small molecule active

    1 trial

  43. CLEE011X2X01B

    Novartis Pharmaceuticals

    Different types of advanced cancer

    phase 2 small molecule active

    1 trial

  44. CLNP023K12201

    Novartis Pharmaceuticals

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  45. CLNP023R12201

    Novartis Pharmaceuticals

    active antineutrophilic cytoplasmic antibody (ANCA) associated vasculitis

    phase 2 small molecule active

    1 trial

  46. CLOU064M12101

    Novartis Pharmaceuticals

    Chronic Inducible urticaria and Chronic Spontaneous Urticaria

    phase 2 small molecule active

    1 trial

  47. CLTP001A12202

    Novartis Pharmaceuticals

    Part A: Healthy volunteers (Part A is not applicable to the EU; for information only) Part B: pulmonary arterial hypertension

    phase 2 small molecule active

    1 trial

  48. CLXH254C12201

    Novartis Pharmaceuticals

    Previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Novartis India have?

121 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.